Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization-Reference-Cited by-同舟云学术

Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization

Published:2023-04-13 Issue:2 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Enaud Raphael¹²³^ORCID,Lussac-Sorton Florian¹²⁴,Charpentier Elena¹²⁴,Velo-Suárez Lourdes⁵⁶,Guiraud Jennifer⁷,Bui Stéphanie¹³,Fayon Michael¹²³,Schaeverbeke Thierry²,Nikolski Macha⁸⁹,Burgel Pierre-Régis¹⁰¹¹,Héry-Arnaud Geneviève⁵¹²,Delhaes Laurence¹²³⁴,

Affiliation:

1. Bordeaux University, INSERM U1045, Centre de Recherche Cardio-thoracique de Bordeaux, Bordeaux, France

2. Bordeaux University Hospital, Bordeaux University, FHU ACRONIM, Bordeaux, France

3. Bordeaux University Hospital, CRCM Pédiatrique, CIC 1401, Bordeaux, France

4. Bordeaux University Hospital, Service de Parasitologie-Mycologie, Bordeaux, France

5. Brest University, EFS, UMR 1078, GGB, INSERM, Brest, France

6. Brest Center for Microbiota Analysis (CBAM), CHU Brest, Brest, France

7. Bordeaux University Hospital, Service de Bactériologie, Bordeaux, France

8. Bordeaux University, Bordeaux Bioinformatics Center, Bordeaux, France

9. Bordeaux University, CNRS, Institut de Biochimie et Génétique Cellulaires (IBGC) UMR 5095, Talence, France

10. Université de Paris, Institut Cochin, INSERM U1016, Paris, France

11. Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Respiratory Medicine and National Reference Cystic Fibrosis Reference Center, Paris, France

12. Brest University Hospital, Department of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest, France

Abstract

The management of cystic fibrosis has been transformed recently by the advent of CFTR modulators, including lumacaftor-ivacaftor. However, the effects of such therapies on the airway ecosystem, particularly on the microbiota-mycobiota and local inflammation, which are involved in the evolution of pulmonary damage, are unclear.

Funder

Association Vaincre la Mucoviscidose

Vertex Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.02251-22

Reference67 articles.

1. Cystic fibrosis

2. Lung microbiota across age and disease stage in cystic fibrosis